A Research Study to See if a Change in Therapy for HIV Infection Can Improve the Immune Response to Treatment
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Our goal is to determine if a change in therapy to one containing Kaletra can improve the
immune response in patients who have previously been immune partial responders or
non-responders. We also are interested in knowing if this agent improves immune response by
affecting cluster of differentiation 4 (CD4) + T cell death (apoptosis) or by further
inhibiting (preventing) ongoing, low-level, viral replication to levels below detection by
current viral load measurements. This will help us understand why immune responses to
effective antiretroviral therapy are so different and help determine some possible guidelines
for managing patients with poor immune responses.
Hypothesis: Patients with poor immune responses to HAART who receive Kaletra in place of
their current PI or Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) while continuing
their current 2 NRTI backbone will have improved immune response to therapy compared to
patients who continue their current regimen.